Summary
Peter Diamandis interviews Naveen Jain (CEO, Viome) and Guru Banavar (CTO, Viome, ex-IBM Watson) on using AI and RNA analysis to prevent and reverse chronic disease through precision nutrition. Viome’s thesis: DNA is static and cannot explain disease onset or progression, but RNA expression — both human and microbial — reveals dynamic biological state. They’ve collected 52.5 quadrillion biological data points (claimed largest database on humanity), building digital twins that model oral microbiome, gut microbiome, and blood biomarkers to predict disease risk and personalize food/supplement recommendations. Viome received FDA breakthrough device designation for detecting oral/throat cancer at stage 1 (95% specificity, 90% sensitivity) from saliva samples alone.
Key Segments
- [00:03] 97% of healthcare dollars spent on chronic diseases; system designed for acute/infectious care
- [00:05] RNA vs DNA thesis: DNA doesn’t change with disease; 99% of expressed genes come from microbiome, not parents
- [00:08] Digitization as prerequisite: analog healthcare can’t leverage AI; must digitize biology first
- [00:12] Guru on IBM Watson to Viome: healthcare data was on delivery side, not biology; RNA changes that
- [00:18] Viome moonshot: use food as medicine to change gene expression and restore homeostasis
- [00:20] Origin story: found RNA technology at Los Alamos National Lab (biodefense program), licensed it
- [00:26] Personalized nutrition: don’t eat broccoli (sulfide), avoid spinach (oxalates), custom supplements via robotic pharmacy
- [00:32] FDA breakthrough device designation for oral/throat cancer detection from saliva RNA
- [00:33] Digital twin concept: biological model enabling glycemic response prediction, disease risk scoring, intervention simulation
Notable Claims
- 52.5 quadrillion biological data points collected (claimed largest on humanity)
- 70% of immune cells are along the gut lining
- 99% of genes expressed in the body come from microbiome, not human genome
- FDA breakthrough device designation for stage 1 oral cancer detection (95% specificity, 90% sensitivity)
- 600,000+ samples analyzed with longitudinal follow-up
- Naveen Jain: chronologically 64, biologically 52 per Viome metrics
Guests
- Naveen Jain — CEO, Viome
- Guru Banavar — CTO & Head of AI, Viome (ex-IBM Watson)
RDCO Mapping
- AI + biology convergence: RNA analysis as enabling layer for precision health, similar to Colossal’s synthetic biology approach
- Platform data moats: quadrillion-scale proprietary biological datasets as competitive advantage
- Digital twin biology: personalized biological models enabling predictive and interventional medicine
- Sponsor note: Diamandis is investor (Bold Capital on board); Fountain Life mid-roll ad also his company — high founder-product entanglement
Related
- ai-health
- precision-medicine
- microbiome
- digital-twin
- longevity